A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years

Boston Clinical Trials Inc - Internal Medicine, Boston, Massachusetts, United States

Quest Research Institute, Farmington Hills, Michigan, United States

Sharlin Health & Neurology, Ozark, Missouri, United States

Washington University School of Medicine Neurology Clinical Unit, St Louis, Missouri, United States

Oklahoma Medical Research Foundation (OMRF) MS Center of Excellence, Oklahoma City, Oklahoma, United States

University of Texas Southwestern Medical Center, Dallas, Texas, United States

ANESC Research, El Paso, Texas, United States

Saturn Research Solutions, Plano, Texas, United States

University of the Sunshine Coast Clinical Trials, Birtinya, Queensland, Australia

North Bristol NHS Trust - Southmead Hospital, Bristol, United Kingdom

Cardiff and Vale University Health Board - University Hospital Wales, Cardiff, United Kingdom

Anne Rowling Regenerative Neurology Clinic, University of Edinburgh, Edinburgh, United Kingdom

NHS Greater Glasgow & Clyde - Institute of Neurological Sciences, Glasgow, United Kingdom

Cambridge Clinical Research Centre, London, United Kingdom

East Kent Hospitals University NHS Foundation Trust, London, United Kingdom

The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom

Sheffield Teaching Hospital NHS foundation Trust, Herries Road, Sheffield, United Kingdom